
## Javier Martin-Broto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1125258/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	3.2	18
2	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2022, 40, 2479-2490.	0.8	15
3	Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report. Current Problems in Cancer Case Reports, 2022, 6, 100149.	0.1	1
4	A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma Journal of Clinical Oncology, 2022, 40, TPS11582-TPS11582.	0.8	3
5	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVIDâ€19 pandemic: A guide for surgical oncologists. Journal of Surgical Oncology, 2021, 123, 12-23.	0.8	7
6	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Molecular Cancer Therapeutics, 2021, 20, 132-141.	1.9	9
7	SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). Clinical and Translational Oncology, 2021, 23, 922-930.	1.2	26
8	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. Frontiers in Immunology, 2021, 12, 577766.	2.2	16
9	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers, 2021, 13, 792.	1.7	7
10	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research, 2021, 27, 3861-3866.	3.2	22
11	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Medicine, 2021, 10, 2645-2659.	1.3	23
12	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)â <sup>+</sup> t. Annals of Oncology, 2021, 32, 533-541.	0.6	34
13	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
14	What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. Current Opinion in Oncology, 2021, 33, 329-335.	1.1	3
15	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	1.2	13
16	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open, 2021, 6, 100170.	2.0	65
17	A DNA damage repair geneâ€associated signature predicts responses of patients with advanced softâ€ŧissue sarcoma to treatment with trabectedin. Molecular Oncology, 2021, 15, 3691-3705.	2.1	10
18	A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. Cancers, 2021, 13, 2913.	1.7	60

#	Article	IF	CITATIONS
19	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2021, 23, 2489-2496.	1.2	3
20	Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ~†. Annals of Oncology, 2021, 32, 1348-1365.	0.6	381
21	A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report. International Journal of Molecular Sciences, 2021, 22, 7514.	1.8	4
22	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 2021, 47, 2173-2181.	0.5	2
23	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology, 2021, 17, 2923-2939.	1.1	10
24	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. European Journal of Surgical Oncology, 2021, 47, 2166-2172.	0.5	29
25	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Molecular Cancer Therapeutics, 2021, 20, 2539-2552.	1.9	2
26	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I. Cancer Treatment Reviews, 2021, 99, 102259.	3.4	6
27	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II. Cancer Treatment Reviews, 2021, 99, 102260.	3.4	7
28	Olaratumab-induced Biomarker Modulation in Sarcomas—Response. Molecular Cancer Therapeutics, 2021, 20, 2094-2094.	1.9	0
29	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. Cancers, 2021, 13, 1.	1.7	189
30	WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. Cancers, 2021, 13, 5521.	1.7	7
31	Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. Lancet Oncology, The, 2020, 21, 16-17.	5.1	3
32	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
33	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	0.6	103
34	Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. Cancers, 2020, 12, 2979.	1.7	7
35	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase lb/ll trial. , 2020, 8, e001561.		85
36	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduction and Targeted Therapy, 2020, 5, 195.	7.1	8

JAVIER MARTIN-BROTO

#	Article	IF	CITATIONS
37	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2020, 20, 957-963.	1.1	8
38	Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas. Cancers, 2020, 12, 2556.	1.7	15
39	Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers, 2020, 12, 3740.	1.7	14
40	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. Journal of Clinical Oncology, 2020, 38, 2178-2186.	0.8	145
41	CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (CEIS) Study. Cancers, 2020, 12, 1128.	1.7	6
42	Cancer Stem Cells in Soft-Tissue Sarcomas. Cells, 2020, 9, 1449.	1.8	11
43	Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open, 2020, 5, e000604.	2.0	11
44	New drugs in gastrointestinal stromal tumors. Current Opinion in Oncology, 2020, 32, 314-320.	1.1	16
45	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. JAMA Surgery, 2020, 155, e200397.	2.2	29
46	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a firstâ€line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer, 2020, 126, 2637-2647.	2.0	86
47	Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. Clinical Cancer Research, 2020, 26, 5801-5808.	3.2	26
48	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. JAMA Oncology, 2020, 6, 535.	3.4	33
49	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 456-466.	5.1	51
50	International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol. Trials, 2020, 21, 96.	0.7	56
51	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer, 2020, 20, 99.	1.1	31
52	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Review of Anticancer Therapy, 2020, 20, 15-28.	1.1	6
53	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. JAMA - Journal of the American Medical Association, 2020, 323, 1266.	3.8	190
54	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1252-1262.	5.1	57

#	Article	IF	CITATIONS
55	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	6.3	273
56	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine, 2019, 9, 35-43.	3.2	49
57	Pazopanib in the treatment of advanced solitary fibrous tumour – Authors' reply. Lancet Oncology, The, 2019, 20, e128.	5.1	1
58	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. Sarcoma, 2019, 2019, 1-14.	0.7	4
59	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). Oncologist, 2019, 24, e338-e346.	1.9	44
60	In Reply. Oncologist, 2019, 24, e401-e402.	1.9	0
61	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. Oncologist, 2019, 24, e536-e541.	1.9	26
62	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. Future Oncology, 2019, 15, 17-23.	1.1	3
63	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 134-144.	5.1	97
64	Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin. , 2019, , .		0
65	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of Cancer, 2018, 93, 28-36.	1.3	49
66	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. JAMA Oncology, 2018, 4, e180219.	3.4	63
67	Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. Investigational New Drugs, 2018, 36, 468-475.	1.2	14
68	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	1.7	8
69	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 2018, 23, 62-70.	1.9	62
70	Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv79-iv95.	0.6	380
71	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. Clinical Sarcoma Research, 2018, 8, .	2.3	3
72	Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv68-iv78.	0.6	413

#	Article	IF	CITATIONS
73	Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv51-iv67.	0.6	641
74	Options for treating different soft tissue sarcoma subtypes. Future Oncology, 2018, 14, 25-49.	1.1	35
75	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research, 2018, 24, 5239-5249.	3.2	21
76	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. Oncotarget, 2018, 9, 17576-17588.	0.8	1
77	Tumores del estroma gastrointestinal: breve actualización y consenso de la SEAP-SEOM sobre diagnóstico patológico y molecular. Revista Espanola De Patologia, 2017, 50, 89-99.	0.6	0
78	GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treatment Reviews, 2017, 55, 107-119.	3.4	114
79	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	5.1	370
80	Review of past and present clinical cases with a view to future treatment options. Future Oncology, 2017, 13, 11-28.	1.1	4
81	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Annals of Oncology, 2017, 28, 1230-1242.	0.6	168
82	Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. Molecular Cancer Therapeutics, 2017, 16, 1166-1176.	1.9	16
83	The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncology, 2017, 13, 23-31.	1.1	12
84	Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis. Clinical and Translational Oncology, 2017, 19, 536-545.	1.2	18
85	Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemotherapy and Pharmacology, 2017, 80, 1113-1131.	1.1	30
86	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	0.6	45
87	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer, 2017, 117, 1278-1285.	2.9	33
88	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British Journal of Cancer, 2017, 117, 767-774.	2.9	17
89	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSC). Annals of Oncology, 2017, 28, 2399-2408.	0.6	274
90	Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide. Cancer Translational Medicine, 2017, 3, 20.	0.2	2

JAVIER MARTIN-BROTO

#	Article	IF	CITATIONS
91	Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. Current Opinion in Oncology, 2016, 28, 338-344.	1.1	5
92	SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clinical and Translational Oncology, 2016, 18, 1213-1220.	1.2	34
93	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Clinical and Translational Oncology, 2016, 18, 1221-1228.	1.2	18
94	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. Journal of Clinical Oncology, 2016, 34, 2294-2302.	0.8	61
95	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology, 2016, 27, 2283-2288.	0.6	90
96	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. Annals of Oncology, 2016, 27, vi587.	0.6	17
97	Phase II, singlearm, nonrandomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the firstline setting for patients with metastatic and/or unresectable KIT/PDGFR wild-type GIST. A CEIS and ISG study. Annals of Oncology, 2016, 27, vi492.	0.6	1
98	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clinical Sarcoma Research, 2016, 6, 10.	2.3	1
99	Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemotherapy and Pharmacology, 2016, 77, 133-146.	1.1	40
100	Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. PLoS ONE, 2016, 11, e0155946.	1.1	11
101	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget, 2016, 7, 67033-67046.	0.8	23
102	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future Oncology, 2015, 11, 15-24.	1.1	10
103	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. European Journal of Cancer, 2015, 51, 1611-1617.	1.3	63
104	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and	0.8	148
105	Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 2015, 33, 4276-4283. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncology, The, 2015, 16, e71-e83.	5.1	367
106	Giant cell tumour of bone: new treatments in development. Clinical and Translational Oncology, 2015, 17, 419-430.	1.2	77
107	Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). Annals of Surgical Oncology, 2015, 22, 2948-2957.	0.7	47
108	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	1.9	26

#	Article	IF	CITATIONS
109	Indirect comparisons in cost-effectiveness analysis: are we being naÃ <sup>-</sup> ve?. Clinical and Translational Oncology, 2015, 17, 85-86.	1.2	1
110	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. Journal of Clinical Oncology, 2015, 33, 3628-3634.	0.8	59
111	RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas. Cancer Investigation, 2015, 33, 440-450.	0.6	20
112	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	1.1	8
113	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	1.9	30
114	Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (CEIS) study. Investigational New Drugs, 2014, 32, 287-294.	1.2	10
115	GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemotherapy and Pharmacology, 2014, 74, 883-898.	1.1	42
116	Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. Acta Oncológica, 2014, 53, 1173-1179.	0.8	57
117	Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. Journal of Nutritional Biochemistry, 2014, 25, 429-438.	1.9	22
118	Quality of surgery and neoadjuvant combined therapy in the ISC-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Annals of Oncology, 2013, 24, 817-823.	0.6	69
119	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma, 2012, 2012, 1-11.	0.7	50
120	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii100-vii109.	0.6	65
121	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Journal of Clinical Oncology, 2012, 30, 850-856.	0.8	156
122	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii49-vii55.	0.6	174
123	Adjuvant therapy in primary GIST: state-of-the-art. Annals of Oncology, 2012, 23, 2776-2781.	0.6	67
124	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, 2012, 18, 4458-4464.	3.2	194
125	Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas. PLoS ONE, 2012, 7, e37735.	1.1	38
126	Tumor response assessment by modified Choi criteria in localized highâ€risk soft tissue sarcoma treated with chemotherapy. Cancer, 2012, 118, 5857-5866.	2.0	85

#	Article	IF	CITATIONS
127	SEOM guidelines for gastrointestinal stromal sarcomas (GIST). Clinical and Translational Oncology, 2012, 14, 536-540.	1.2	5
128	SEOM clinical guidelines for the management of adult soft tissue sarcomas. Clinical and Translational Oncology, 2012, 14, 541-544.	1.2	14
129	Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action. European Journal of Pharmacology, 2011, 658, 57-64.	1.7	18
130	Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology, 2011, 29, 2528-2533.	0.8	249
131	Clinical implications of KIT and PDGFRA genotyping in GIST. Clinical and Translational Oncology, 2010, 12, 670-676.	1.2	33
132	Prognostic value of serum CA125 levels in diffuse large Bâ€cell lymphoma: potential role of a new sexâ€ and ageâ€adjusted reference value. International Journal of Laboratory Hematology, 2010, 32, 582-589.	0.7	9
133	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Annals of Oncology, 2010, 21, 1552-1557.	0.6	64
134	Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 2009, 27, 1893-1898.	0.8	64
135	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. New England Journal of Medicine, 2009, 361, 766-776.	13.9	448
136	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). European Journal of Cancer, 2009, 45, 1103-1106.	1.3	31
137	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	5.1	430
138	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Modern Pathology, 2008, 21, 476-484.	2.9	165
139	Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma, 2006, 2006, 1-8.	0.7	7
140	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British Journal of Cancer, 2006, 94, 1797-1802.	2.9	2
141	Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. Pediatric Surgery International, 2006, 22, 967-973.	0.6	33
142	A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. Cancer, 2005, 104, 1706-1712.	2.0	93
143	A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clinical and Translational Oncology, 2005, 7, 66-73.	1.2	10
144	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma, 2005, 9, 127-132.	0.7	27

#	Article	IF	CITATIONS
145	Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Journal of Clinical Oncology, 2005, 23, 6190-6198.	0.8	336
146	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). Journal of Neuro-Oncology, 2004, 70, 359-370.	1.4	32
147	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology, 1998, 9, 871-876.	0.6	57
148	Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology, 1998, 9, 783-785.	0.6	4